Moleculin Biotech Inc (MBRX)

04:17 AM

Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

04:17 AM

03:02 AM

Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade

03:02 AM

01:48 AM

Moleculin Shares Drop 17% Despite Positive Phase 1 WP1066 Data In Pediatric Brain Tumors - Nasdaq

01:48 AM

11:33 AM

Moleculin Biotech Prepares for 1-for-25 Reverse Split Amidst Clinical Advancements - timothysykes.com

11:33 AM

10:42 AM

Moleculin Biotech shares slide after release of pediatric brain tumor trial data - MSN

10:42 AM

10:10 AM

Moleculin's WP1066 Shows Immune Activity, Favorable Safety In Pediatric Brain Cancer Trial - Nasdaq

10:10 AM

09:55 AM

Moleculin announces positive phase 1 data for WP1066 in pediatric brain tumors - marketscreener.com

09:55 AM

09:19 AM

Moleculin Biotech’s Reverse Split Shocks Market - timothysykes.com

09:19 AM

09:15 AM

Moleculin Biotech stock falls after pediatric brain tumor trial results - Investing.com

09:15 AM

09:13 AM

Moleculin’s brain cancer drug shows promise in pediatric trial - Investing.com India

09:13 AM

09:05 AM

Moleculin Biotech Reports Positive Phase 1 Trial Results - TipRanks

09:05 AM

08:49 AM

Moleculin’s brain cancer drug shows promise in pediatric trial By Investing.com - Investing.com South Africa

08:49 AM

08:42 AM

Moleculin Biotech Reports Positive Phase 1 Trial Results for WP1066 in Pediatric Brain Cancer Treatments - Quiver Quantitative

08:42 AM

08:33 AM

Moleculin Biotech, Inc. Announces Positive Phase 1 Trial Results for WP1066 - TradingView — Track All Markets

08:33 AM

08:31 AM

Moleculin Announces Positive Results from Phase 1 Clinical - GlobeNewswire

08:31 AM

Dec 16, 2025

Moleculin Biotech regains compliance with Nasdaq minimum bid price rule By Investing.com - Investing.com Nigeria

Dec 16, 2025

Dec 16, 2025

Moleculin Biotech Regains Nasdaq Compliance - TipRanks

Dec 16, 2025

Dec 16, 2025

Moleculin Biotech regains compliance with Nasdaq minimum bid price rule - Investing.com India

Dec 16, 2025

Dec 15, 2025

Moleculin Biotech (MBRX) Target Price Adjusted by Roth Capital A - GuruFocus

Dec 15, 2025

Dec 14, 2025

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN

Dec 14, 2025

Dec 13, 2025

CapEx per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView — Track All Markets

Dec 13, 2025

Dec 12, 2025

Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN

Dec 12, 2025

Dec 11, 2025

Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade - GuruFocus

Dec 11, 2025

Dec 11, 2025

HC Wainwright & Co. Maintains Moleculin Biotech (MBRX) Buy Recommendation - Nasdaq

Dec 11, 2025

Dec 11, 2025

Moleculin Biotech raises $6.5 million through warrant exercise By Investing.com - Investing.com Nigeria

Dec 11, 2025

Dec 10, 2025

Moleculin Biotech Enters Inducement Offer Agreements - TipRanks

Dec 10, 2025

Dec 10, 2025

Moleculin Biotech stock falls after warrant exercise agreement By Investing.com - Investing.com South Africa

Dec 10, 2025

Dec 10, 2025

Moleculin Biotech stock falls after warrant exercise agreement - Investing.com India

Dec 10, 2025

Dec 10, 2025

Moleculin Biotech raises $6.5 million through warrant exercise - Investing.com

Dec 10, 2025

Dec 10, 2025

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - The Manila Times

Dec 10, 2025

Dec 10, 2025

Moleculin Biotech, Inc. Announces Immediate Exercise of Warrants for Gross Proceeds of Approximately $6.5 Million - Quiver Quantitative

Dec 10, 2025

Dec 10, 2025

Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan

Dec 10, 2025

Dec 09, 2025

Moleculin Biotech (MBRX) Stock: Faces Market Drop Despite Positive MIRACLE Trial Enrollment Progress - parameter.io

Dec 09, 2025

Dec 09, 2025

Moleculin Biotech (MBRX) Approaches Key Enrollment Milestone in Leukemia Study - GuruFocus

Dec 09, 2025

Dec 09, 2025

Moleculin Biotech Updates on MIRACLE Study Progress - TipRanks

Dec 09, 2025

Dec 09, 2025

Moleculin stock rises as AML trial enrollment reaches 78% By Investing.com - Investing.com Nigeria

Dec 09, 2025

Dec 09, 2025

Moleculin Biotech, Inc. Updates on MIRACLE Phase 2B/3 AML Trial Progress - TradingView — Track All Markets

Dec 09, 2025

Dec 09, 2025

Moleculin stock rises as AML trial enrollment reaches 78% - Investing.com

Dec 09, 2025

Dec 09, 2025

Moleculin reports 78% enrollment in AML treatment trial - Investing.com

Dec 09, 2025

Dec 09, 2025

Moleculin reports 78% enrollment in AML treatment trial By Investing.com - Investing.com South Africa

Dec 09, 2025

Dec 09, 2025

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal 'MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - The Manila Times

Dec 09, 2025

Dec 09, 2025

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - Sahm

Dec 09, 2025

Dec 09, 2025

Moleculin Announces Completion of Treatment for the 45 - GlobeNewswire

Dec 09, 2025

Dec 09, 2025

The MIRACLE Test: Trial Progress And Market Moves Put Moleculin In Focus - RTTNews

Dec 09, 2025

Dec 09, 2025

Moleculin (Nasdaq: MBRX) Tracks Toward 45-Patient MIRACLE AML Readout in Q1 2026 - Stock Titan

Dec 09, 2025

Dec 08, 2025

Moleculin enters research agreement for brain cancer treatment By Investing.com - Investing.com Australia

Dec 08, 2025

Dec 08, 2025

After tax other income/expense of Moleculin Biotech, Inc. – BER:MOL0 - TradingView — Track All Markets

Dec 08, 2025

Dec 08, 2025

Moleculin Biotech Partners with CIC biomaGUNE for Research - TipRanks

Dec 08, 2025

Dec 08, 2025

Moleculin Biotech (MBRX) Partners with CIC biomaGUNE for Brain C - GuruFocus

Dec 08, 2025